(Q44948356)

7 December 2017

title

Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours (English)

1 reference

7 December 2017

1 reference

Yves Humblet

1

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

Expert Opinion on Pharmacotherapy

7 December 2017

published in

1 reference

7 December 2017

volume

5

1 reference

7 December 2017

issue

7

1 reference

7 December 2017

page(s)

1621-1633

1 reference

Epithelioid and fibroblastic rat kidney cell clones: Epidermal growth factor (EGF) receptors and the effect of mouse sarcoma virus transformation

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1621

C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1621

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1621

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1621

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1621

Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1621

Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1621

Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1621

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1621

The chemotherapy of colon cancer can no longer be ignored

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1621

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1621

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1621

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1621

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1621

Evaluation of the newly updated TNM classification of head and neck carcinoma with data from 3247 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1621

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1621

10.1517/14656566.5.7.1621

21 January 2018

Identifiers

DOI

1 reference

7 December 2017

1 reference